USP13 Inhibitor for Mitophagy and Synaptic Proteostasis

USP13 Deubiquitinase Inhibition for Parkin-Independent Mitophagy Rescue

Overview

This therapeutic strategy targets USP13 (Ubiquitin-Specific Peptidase 13), a deubiquitinating enzyme that counteracts the ubiquitin-tagging of both Parkin and α-synuclein, thereby blocking their proteasomal degradation and impairing PINK1-Parkin mitophagy. Pharmacological inhibition of USP13 would restore ubiquitin-dependent clearance of damaged mitochondria and toxic α-synuclein species even in neurons with impaired Parkin function — a common feature of both familial and sporadic Parkinson's disease.[@liu2019][@liu2019a]

Target

• Primary Target: USP13 (Ubiquitin-Specific Peptidase 13 / Isopeptidase T-3)
• Target Type: Small-molecule catalytic-site inhibitor[@mevissen2017]
• Expression: Broadly expressed; enriched in substantia nigra dopaminergic neurons and cortical neurons vulnerable in Lewy body dementia
• Localization: Cytoplasm and outer mitochondrial membrane, where it opposes Parkin-mediated ubiquitination[@bingol2014]

Mechanistic Rationale

The PINK1-Parkin mitophagy pathway is the principal quality-control mechanism for damaged mitochondria in neurons.[@pickrell2015] When mitochondrial membrane potential collapses, PINK1 accumulates on the outer membrane and recruits Parkin, which ubiquitinates mitochondrial surface proteins to flag them for autophagic clearance.[@narendra2008] USP13 directly opposes this process at two levels:

...

USP13 Deubiquitinase Inhibition for Parkin-Independent Mitophagy Rescue

Overview

This therapeutic strategy targets USP13 (Ubiquitin-Specific Peptidase 13), a deubiquitinating enzyme that counteracts the ubiquitin-tagging of both Parkin and α-synuclein, thereby blocking their proteasomal degradation and impairing PINK1-Parkin mitophagy. Pharmacological inhibition of USP13 would restore ubiquitin-dependent clearance of damaged mitochondria and toxic α-synuclein species even in neurons with impaired Parkin function — a common feature of both familial and sporadic Parkinson's disease.[@liu2019][@liu2019a]

Target

• Primary Target: USP13 (Ubiquitin-Specific Peptidase 13 / Isopeptidase T-3)
• Target Type: Small-molecule catalytic-site inhibitor[@mevissen2017]
• Expression: Broadly expressed; enriched in substantia nigra dopaminergic neurons and cortical neurons vulnerable in Lewy body dementia
• Localization: Cytoplasm and outer mitochondrial membrane, where it opposes Parkin-mediated ubiquitination[@bingol2014]

Mechanistic Rationale

The PINK1-Parkin mitophagy pathway is the principal quality-control mechanism for damaged mitochondria in neurons.[@pickrell2015] When mitochondrial membrane potential collapses, PINK1 accumulates on the outer membrane and recruits Parkin, which ubiquitinates mitochondrial surface proteins to flag them for autophagic clearance.[@narendra2008] USP13 directly opposes this process at two levels:

Deubiquitinates Parkin itself — removing the ubiquitin chains that activate and stabilize Parkin, reducing its E3 ligase activity[@liu2019]

Deubiquitinates α-synuclein — rescuing misfolded α-synuclein from proteasomal degradation, increasing its cytoplasmic burden and promoting aggregation[@liu2019a]

Impairs mitophagy completion — by stripping ubiquitin from OMM substrates (MFN2, VDAC1, TOM20), USP13 prevents autophagy receptor recruitment[@harper2018]

Genetic knockdown of USP13 in MPTP-treated mice dramatically rescued dopaminergic neuron survival, reduced α-synuclein accumulation, and restored mitochondrial function — even with partial Parkin deficiency.[@liu2019]

Cross-links to relevant mechanisms:

• PINK1-Parkin Mitophagy Pathway
• Mitophagy
• Mitophagy Receptor Pathway
• Protein Aggregation in Neurodegeneration
• Alpha-Synuclein Aggregation
• Mitochondrial Dysfunction

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 9/10 | USP13 is a virtually unexplored clinical target; no DUB inhibitors in neurodegeneration trials |
| Mechanistic Rationale | 8/10 | Strong genetic and pharmacological evidence in PD mouse models; clear molecular mechanism |
| Addresses Root Cause | 8/10 | Directly restores mitochondrial quality control and α-synuclein clearance — two core PD pathologies |
| Delivery Feasibility | 7/10 | Small-molecule DUB inhibitors are well-precedented in oncology; BBB penetration achievable |
| Safety Plausibility | 6/10 | USP13 has broad substrate repertoire; selectivity engineering needed to avoid off-target deubiquitination |
| Combinability | 8/10 | Orthogonal to dopaminergic therapies, anti-inflammatory approaches, and GCase activators like ambroxol |
| Biomarker Availability | 7/10 | CSF α-synuclein seed amplification, NfL, and mitochondrial-derived vesicle markers can track target engagement |
| De-risking Path | 7/10 | iPSC-derived dopaminergic neuron models with PINK1/PRKN mutations available; MPTP mouse model validated |
| Multi-disease Potential | 7/10 | Applicable to PD, DLB, MSA (synucleinopathies), and potentially AD (mitophagy impairment) and ALS (TDP-43 ubiquitin pathology) |
| Patient Impact | 8/10 | Could halt dopaminergic neuron loss if administered early; disease-modifying rather than symptomatic |
| Total | 75/100 | |

De-risking Path

Phase 1 — Target validation: Confirm USP13 knockdown/inhibition in human iPSC-derived dopaminergic neurons from PINK1, PRKN, and GBA1 mutation carriers rescues mitophagy and reduces phospho-α-synuclein

Phase 2 — Hit discovery: Screen DUB-focused compound libraries using fluorogenic ubiquitin-AMC assays and AlphaFold-guided virtual screening of the USP13 catalytic site

Phase 3 — Selectivity profiling: Counter-screen against USP7, USP14, USP30 (the DUBs with overlapping substrates) using activity-based ubiquitin probes

Phase 4 — In vivo PK/PD: Demonstrate BBB penetration, brain target engagement (measure mitochondrial ubiquitination levels), and tolerability in rodents

Phase 5 — Efficacy: Test in AAV-α-synuclein PFF injection model and MitoPark mice; primary endpoints: DA neuron survival, striatal dopamine, rotarod/cylinder behavior

Actionable Next Steps

Lab Experiments (Proof-of-Concept & Target Validation)

iPSC Neuron Validation

• Obtain iPSC lines from PINK1, PRKN, and GBA1 mutation carriers
• Differentiate to dopaminergic neurons and confirm USP13 knockdown via siRNA/shRNA
• Measure: mitophagy flux (mito-Keima), phospho-α-synuclein levels, mitochondrial function ( Seahorse)
• Timeline: 3-4 months
• Estimated cost: $80,000-120,000

Hit Discovery Campaign

• Screen 50,000+ compound library (NIH Clinical Collection, DUB-focused library)
• Primary assay: fluorogenic ubiquitin-AMC cleavage
• Secondary: Cell-based mitophagy rescue in USP13-overexpressing cells
• Timeline: 2-3 months
• Estimated cost: $50,000-80,000

Selectivity Profiling

• Counter-screen against USP7, USP14, USP30, USP10, USP5
• Use activity-based ubiquitin-probe labeling
• Timeline: 1-2 months
• Estimated cost: $30,000-50,000

Clinical Protocol Design

First-in-Human Study Design

• Phase 1a: Single ascending dose in healthy volunteers (24 subjects)
• Phase 1b: Multiple ascending dose (28 days) with PK/PD biomarkers
• Key biomarkers: CSF α-synuclein seeding (RT-QuIC), NfL, mitochondrial-derived vesicles
• Timeline: 18-24 months for Phase 1
• Estimated cost: $3-5M

Patient Population

• Early-stage Parkinson's disease (Hoehn & Yahr 1-2)
• Confirmed synucleinopathy via DaTscan
• Exclusion: on MAO-B inhibitors, prior neurosurgery
• Target enrollment: 60-100 patients

Partnership Targets

| Partner Type | Target Organization | Rationale |
|-------------|---------------------|-----------|
| Pharma | AbbVie, BMS, Pfizer | Existing DUB inhibitor programs; oncology-to-neuro pipeline interest |
| Biotech | NeuBase, Prothelia | Gene therapy and antisense capabilities |
| Academic | Michael J. Fox Foundation | Preclinical consortia, patient cohorts |
| Academic | CEP (Center for Neurodegeneration Research) | iPSC lines, PD models |
| VC | Andreessen Horowitz, ARCH, GV | Neurodegeneration-focused funds |

Grant Opportunities

| Grant | Agency | Amount | Focus | Deadline |
|-------|--------|--------|-------|----------|
| R21 | NIH/NINDS | $275K | Target validation, hit-to-lead | April 2026 |
| U01 | NIH/NINDS | $3M | Preclinical development | Sept 2026 |
| SBIR Phase I | NIH | $300K | Drug discovery | Rolling |
| MJFF Therapeutics | Michael J. Fox | $500K-1M | PD drug development | Q2 2026 |
| ASAP | Aligning Science Across Parkinson's | $500K-2M | Preclinical consortia | Q1, Q3 |

Cost Estimates

| Phase | Estimated Cost | Duration |
|-------|----------------|----------|
| Target Validation | $150K | 6 months |
| Hit Discovery & SAR | $500K | 12 months |
| Lead Optimization | $1.5M | 18 months |
| IND-enabling studies | $3M | 12 months |
| Phase 1 | $5M | 24 months |
| Total to Phase 1 | ~$10M | ~72 months |

Timeline

Key Milestones:

• Q3 2026: Complete iPSC validation
• Q1 2027: Identify 3-5 lead compounds
• Q2 2028: Select clinical candidate
• Q3 2029: Submit IND
• Q1 2030: Begin Phase 1 enrollment

Disease Coverage

| Disease | Relevance | Rationale |
|---------|-----------|-----------|
| Parkinson's Disease | High | Core PINK1-Parkin pathway defect; α-synuclein accumulation |
| Dementia with Lewy Bodies | High | Shared synuclein pathology with cortical involvement |
| Multiple System Atrophy | Medium | Oligodendroglial α-synuclein aggregation; mitophagy role less clear |
| Alzheimer's Disease | Medium | Mitophagy impairment documented; Parkin deficiency in hippocampal neurons[@hebron2014] |
| ALS/FTD | Low | TDP-43 ubiquitin pathology present but USP13 role not validated[@peng2003] |

Combination Therapy Potential

• With GCase activators: USP13 inhibition restores ubiquitin-dependent clearance while ambroxol enhances lysosomal degradation — orthogonal mechanisms converging on α-synuclein reduction[@durcan2015]
• With NAD+ precursors: NR/NMN replenish the NAD+ pool depleted by damaged mitochondria while USP13 inhibition accelerates mitophagy of those mitochondria
• With LRRK2 kinase inhibitors: LRRK2 phosphorylates Rab GTPases involved in vesicular trafficking; combining with USP13 inhibition addresses both trafficking and ubiquitin arms of mitophagy

Related NeuroWiki Pages

• PINK1 Gene | PINK1 Protein
• PRKN Gene | Parkin Protein
• Alpha-Synuclein | SNCA Gene
• GBA1 Gene | GCase Protein
• Mitophagy | Mitochondrial Dysfunction
• VPS35 Pathway | Retromer Complex
• [Dopaminergic Neurodegeneration](/mechanisms/dopaminergic-neurodegeneration)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Implementation Roadmap

Phase 1: Discovery (6-12 months)

Target Validation

• Confirm USP13 involvement in tau/LB clearance via siRNA knockdown
• Demonstrate that USP13 inhibition enhances mitophagy flux
• Validate in patient-derived neurons (iPSC)

Lead Identification

• Virtual screening of 100K compound library against USP13
• High-throughput screening of FDA-approved drugs
• Fragment-based drug design for novel chemotypes

Phase 2: Lead Optimization (12-18 months)

Medicinal Chemistry

• Develop structure-activity relationship (SAR)
• Improve potency (IC50 < 100nM), selectivity (100x vs USP10, USP5)
• Optimize brain penetration (Cbrain/Cplasma > 0.1)

Preclinical Development

• In vitro ADME profiling (CYP inhibition, plasma protein binding)
• In vivo PK/PD in tauopathy mouse models
• GLP toxicology initiation

Phase 3: Clinical Development (24-36 months)

IND-enabling studies

• Complete GLP toxicology (rodent, non-rodent)
• CMC scale-up for Phase 1

Clinical Trials

• Phase 1: Single/multiple ascending dose in healthy volunteers
• Phase 2: Biomarker-confirmed early AD/PD patients

Estimated Cost to IND: $8-12M Estimated Cost Phase 1-2: $25-40M

Next Steps

Immediate Priorities (0-6 months)

USP13 inhibitor screening: Virtual screening of covalent libraries for USP13 hits, followed by structure-activity relationship optimization

Blood-brain barrier optimization: Design USP13 inhibitors with LogP < 3, PSA < 80 for CNS penetration

Target engagement biomarkers: Develop assays for ubiquitylated mitochondrial proteins in CSF

Research Gaps to Address

• Validate USP13 selectivity vs. other deubiquitinases (USP10, USP30)
• Determine therapeutic window for mitophagy induction without disrupting essential cellular processes
• Assess long-term effects of chronic mitophagy enhancement

Clinical Development Path

Phase 1: First-in-human single/multiple ascending dose (n=64)

Phase 2: Biomarker-guided study in GBA-PD patients (n=60) - high glucocerebrosidase dysfunction

Primary endpoint: Mitophagy markers (phospho-ubiquitin) in peripheral blood mononuclear cells

Secondary endpoints: Motor scores, dopamine transporter imaging

Clinical Site Recommendations

• USA: Emory University (Dr. J. Ravits, GBA expertise), Columbia University (Dr. R. Alcalay)
• EU: University College London (Prof. A. Schapira), Tel Aviv University (Prof. N. Giladi)
• Industry Partner: Prothelia (mitophagy platform), Celgene/BMS

Partnership Opportunities

• Academic: Collaborate with Dr. Richard Youle (NIH) on PINK1/Parkin biology
• Industry: Alliance with GBA therapeutic developers (Biocode, Prevamp)
• Funding: NIH R01 for USP13 biology, Michael J. Fox Foundation for PD translation

Cross-Links

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dementia with Lewy Bodies](/diseases/lewy-body-dementia)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [USP13 Gene](/mechanisms/dopaminergic-neuron-vulnerability)
• [PINK1](/genes/pink1)
• [Mitophagy Mechanisms](/mechanisms/dopaminergic-neuron-vulnerability)
• [Autophagy Mechanisms](/mechanisms/autophagy-mechanisms)
• [Ubiquitin](/proteins/ubiquitin)
• [Parkin Protein](/proteins/prkn-protein)
• [PINK1 Protein](/proteins/PINK1)
• [Alpha](/proteins/alpha-synuclein)
• [Neurons](/entities/neurons)
• [Dopaminergic Neurons](/entities/dopaminergic-neurons)
• [Alpha](/mechanisms/alpha-synuclein-aggregation)
• [Mitochondrial Dynamics](/entities/mitochondrial-dynamics)
• [Small Molecule Inhibitors](/mechanisms/dopaminergic-neuron-vulnerability)
• [Mitophagy](/mechanisms/dopaminergic-neuron-vulnerability)

References

[Liu X, Hebron M, Bhatt P, et al, Ubiquitin specific protease-13 independently regulates parkin ubiquitination and alpha-synuclein clearance in alpha-synucleinopathies (2019)](https://pubmed.ncbi.nlm.nih.gov/30643139/)

[Liu X, Hebron ML, Mulki S, et al, USP13 antagonizes gp78 to maintain functionality of the ubiquitin proteasome system (2019)](https://pubmed.ncbi.nlm.nih.gov/30979833/)

[Harper JW, Ordureau A, Heo JM, Building and decoding ubiquitin chains for mitophagy (2018)](https://pubmed.ncbi.nlm.nih.gov/29420078/)

[Pickrell AM, Youle RJ, The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25527291/)

[Mevissen TET, Komander D, Mechanisms of deubiquitinase specificity and regulation (2017)](https://pubmed.ncbi.nlm.nih.gov/28498656/)

[Bingol B, Tea JS, Phu L, et al, The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy (2014)](https://pubmed.ncbi.nlm.nih.gov/24561620/)

[Narendra D, Tanaka A, Suen DF, Youle RJ, Parkin is recruited selectively to impaired mitochondria and promotes their autophagy (2008)](https://pubmed.ncbi.nlm.nih.gov/18799693/)

[Hebron ML, Lonskaya I, Ober V, et al, Tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in alpha-synucleinopathy (2014)](https://pubmed.ncbi.nlm.nih.gov/25277854/)

[Peng J, Schwartz D, Elias JE, et al, A proteomics approach to understanding protein ubiquitination (2003)](https://pubmed.ncbi.nlm.nih.gov/12872131/)

[Durcan TM, Fon EA, The three P's of mitophagy: PARKIN, PINK1, and post-translational modifications (2015)](https://pubmed.ncbi.nlm.nih.gov/26005864/)

Pathway Diagram

The following diagram shows the key molecular relationships involving USP13 Inhibitor for Mitophagy and Synaptic Proteostasis discovered through SciDEX knowledge graph analysis: